Effect of Multiple Medicines on Dementia Initial Treatment: Experience and Thinking

1. Arbanas, G . Diagnostic and statistical manual of mental disorders (DSM-5). Alcohol Psychiatry Res. 2015;51:61-64.
Google Scholar2. Prince, M, Guerchet, M, Prina, M. The Global Impact of Dementia: 2013-2050. London: Alzheimer’s Disease International; 2013:8.
Google Scholar3. Prince, M, Wimo, A, Guerchet, M, Ali, G-C, Wu, Y-T, Prina, M. World Alzheimer Report 2015. London: Alzheimer’s Disease International; 2015.
Google Scholar4. Livingston, G, Sommerlad, A, Orgeta, V, et al Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6
Google Scholar | Crossref | Medline5. Brunet, MD . Dementia statistic is misleading. BMJ. 2013;347:f6704. doi:10.1136/bmj.f6704
Google Scholar | Crossref | Medline6. Sancho, R, Cox, C, Ridley, S, Phipps, L, Karran, E. Report from the Alzheimer’s Research UK conference 2015. Alzheimer’s Res Ther. 2015;7(1):52. doi:10.1186/s13195-015-0138-x
Google Scholar | Crossref | Medline7. Association. As . 2018 Alzheimer’s disease facts and figures. Alzheimer’s Dementia. 2018;14(3):367-429.
Google Scholar | Crossref8. Matsunaga, S, Kishi, T, Iwata, N. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2015;18(5):pyu115. doi:10.1093/ijnp/pyu115.
Google Scholar | Crossref9. Pereverzev, A, Ostroumova, O, Tkacheva, O, Kotovskaya, Y. Safety of cholinesterase inhibitors and NMDA receptors antagonists for the treatment of patients with dementia. Safe Risk Pharmaco. 2019;7:190-199. doi:10.30895/2312-7821-2019-7-4-190-199
Google Scholar | Crossref10. Prince, M, Bryce, R, Albanese, E, Wimo, A, Ribeiro, W, Ferri, CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s Dementia. 2013;9(1):63-75.e2. doi:10.1016/j.jalz.2012.11.007.
Google Scholar | Crossref | Medline | ISI11. Bohlken, J, Jacob, L, van den Bussche, H, Kostev, K. The influence of polypharmacy on the initiation of anti-dementia therapy in Germany. J Alzheim Dis. 2018;64(3):827-833. doi:10.3233/jad-180382.
Google Scholar | Crossref | Medline12. Nasreddine, ZS, Phillips, NA, Bédirian, V, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2010;53(4):695-699.
Google Scholar | Crossref13. Shulman, KI . Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatr. 2000;15(6):548-561.
Google Scholar | Crossref | Medline | ISI14. Eto, F, Tanaka, M, Chishima, M, et al. Comprehensive Activities of Daily Living (ADL) index for the elderly. Japan Geriatrics. 1992;29(11):841-848.
Google Scholar | Crossref | Medline15. Cummings, JL, Mega, M, Gray, K, Rosenberg-Thompson, S, Carusi, DA, Gornbein, J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308.
Google Scholar | Crossref | Medline | ISI16. Morris, JC . The Clinical Dementia Rating (CDR). Neurology. 1993;43(11):2-2412. doi:10.1212/wnl.43.11.2412-a.
Google Scholar | Crossref17. McKann, G, Drachman, D, Folstein, M. Clinical diagnosis of Alzheimer’s disease. Neurology. 1984;34(7):939-944.
Google Scholar | Medline18. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). Washington, DC: Amencan Psychiatric Publishing.; 2000.
Google Scholar19. Cairns, N, Bigio, E, Mackenzie, I, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathologica. 2007;114(1):5-22. doi:10.1007/s00401-007-0237-2.
Google Scholar | Crossref | Medline | ISI20. Mckeith, IG, Galasko, D, Kosaka, K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB). Neurology. 1996;47(5):1113-1124.
Google Scholar | Crossref | Medline | ISI21. Md, M, Md, D, Brown, R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689-1707. doi:10.1002/mds.21507.
Google Scholar | Crossref | Medline22. Winblad, B, Palmer, K, Kivipelto, M, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2010;256(3):240-246.
Google Scholar | Crossref23. Ju, C, Wong, ICK, Lau, WCY, et al Global trends in symptomatic medication use against dementia in 66 countries/regions from 2008 to 2018. Eur J Neurol. 2021;doi:10.1111/ene.15053
Google Scholar | Crossref24. Masnoon, N, Shakib, S, Kalisch-Ellett, L, Caughey, GE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics. 2017;17(1):230. doi:10.1186/s12877-017-0621-2.
Google Scholar | Crossref | Medline25. Kristensen, RU, Nørgaard, A, Jensen-Dahm, C, Gasse, C, Wimberley, T, Waldemar, G. Polypharmacy and potentially inappropriate medication in people with dementia: a nationwide study. J Alzheim Dis. 2018;63(1):383-394. doi:10.3233/jad-170905.
Google Scholar | Crossref | Medline26. Onder, G, Liperoti, R, Foebel, A, et al Polypharmacy and mortality among nursing home residents with advanced cognitive impairment: results from the SHELTER study. J Am Med Dir Assoc. 2013;14(6):450.e7-450.e12. doi:10.1016/j.jamda.2013.03.014
Google Scholar | Crossref27. Mueller, C, Molokhia, M, Perera, G, et al. Polypharmacy in people with dementia: associations with adverse health outcomes. Exp Gerontol. 2018;106:240-245. doi:10.1016/j.exger.2018.02.011.
Google Scholar | Crossref | Medline28. Leelakanok, N, D’Cunha, RR. Association between polypharmacy and dementia - A systematic review and metaanalysis. Aging Ment Health. 2019;23(8):932-941. doi:10.1080/13607863.2018.1468411.
Google Scholar | Crossref | Medline29. Lai, SW, Lin, CH, Liao, KF, Su, LT, Sung, FC, Lin, CC. Association between polypharmacy and dementia in older people: a population-based case-control study in Taiwan. Geriatr Gerontol Int. 2012;12(3):491-498. doi:10.1111/j.1447-0594.2011.00800.x.
Google Scholar | Crossref | Medline30. Park, HY, Park, JW, Song, HJ, Sohn, HS, Kwon, JW. The Association between polypharmacy and dementia: a nested case-control study based on a 12-year longitudinal cohort database in South Korea. PLoS One. 2017;12(1):e0169463. doi:10.1371/journal.pone.0169463.
Google Scholar | Crossref | Medline31. Prasad, K, Gupta, H, Bharath, S, et al Clinical practice with antidementia and antipsychotic drugs: Audit from a geriatric clinic in India. Indian J Psychiatry. 2009;51(4):272-275. doi:10.4103/0019-5545.58292
Google Scholar | Crossref | Medline32. Hager, K, Mehrtens, T. P4‐012: antidementia drugs in a geriatric clinic. Alzheimer’s Dementia. 2018;14:P1436. doi:10.1016/j.jalz.2018.06.2414
Google Scholar | Crossref33. Tolar, M, Abushakra, S, Hey, JA, Porsteinsson, A, Sabbagh, M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. Alzheimer’s Res Ther. 2020;12(1):95. doi:10.1186/s13195-020-00663-w
Google Scholar | Crossref | Medline34. Schneider, L . A resurrection of aducanumab for Alzheimer’s disease. Lancet Neurol. 2020;19(2):111-112. doi:10.1016/s1474-4422(19)30480-6.
Google Scholar | Crossref | Medline35. Koola, MM . Alpha7 nicotinic‐N‐methyl‐D‐aspartate hypothesis in the treatment of schizophrenia and beyond. Hum Psychopharmacol Clin Exp. 2021;36(1):1-16. doi:10.1002/hup.2758.
Google Scholar | Crossref | Medline36. Koola, MM . Galantamine-Memantine combination in the treatment of Alzheimer’s disease and beyond. Psychiatry Res. 2020;293:113409. doi:10.1016/j.psychres.2020.113409.
Google Scholar | Crossref | Medline37. Woodruff-Pak, DS, Tobia, MJ, Jiao, X, Beck, KD, Servatius, RJ. Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil. Neuropsychopharmacology. 2007;32(6):1284-1294. doi:10.1038/sj.npp.1301259
Google Scholar | Crossref | Medline38. Matsuzono, K, Hishikawa, N, Ohta, Y, et al. Combination therapy of cholinesterase inhibitor (Donepezil or Galantamine) plus memantine in the okayama memantine study. J Alzheim Dis. 2015;45(3):771-780. doi:10.3233/jad-143084.
Google Scholar | Crossref | Medline39. Koola, MM, Nikiforuk, A, Pillai, A, Parsaik, AK. Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer’s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity. J Geriatr Care Res. 2018;5(2):57-67.
Google Scholar | Medline40. Koola, MM . Galantamine-memantine combination for cognitive impairments due to electroconvulsive therapy, traumatic brain injury, and neurologic and psychiatric disorders. Prim Care Companion CNS Disord. 2018;20(2)doi:10.4088/PCC.17nr02235
Google Scholar | Crossref41. Fayed, N, Oliván, B, Lopez Del Hoyo, Y, et al Changes in metabolites in the brain of patients with fibromyalgia after treatment with an NMDA receptor antagonist. Neuroradiol J. 2019;32(6):408-419. doi:10.1177/1971400919857544
Google Scholar | SAGE Journals | ISI42. Moffett, JR, Ross, B, Arun, P, Madhavarao, CN, Namboodiri, AM. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Pro Neurobiol. 2007;81(2):89-131. doi:10.1016/j.pneurobio.2006.12.003.
Google Scholar | Crossref | Medline | ISI43. Koola, MM, Praharaj, SK, Pillai, A. Galantamine-memantine combination as an antioxidant treatment for schizophrenia. Curr Behav Neurosci Rep. 2019;6(2):37-50. doi:10.1007/s40473-019-00174-5
Google Scholar | Crossref | Medline44. Akintade, O, Pierres, F. Acute presentation of dementia with Lewy bodies. Clin Med. 2019;19(4):327-330. doi:10.7861/clinmedicine.19-4-327
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif